Nikkiso Co. Ltd. Announces Consolidated Earnings Results for Nine Months Ended September 30, 2018; Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2018; Provides Dividend Guidance for the Fiscal Year Ending December 31, 2018
November 13, 2018
Share
Nikkiso Co. Ltd. announced consolidated earnings results for nine months ended September 30, 2018. For the period, the company reported revenue of JPY 115,437 million compared to JPY 97,199 million a year ago. Operating profit was JPY 6,308 million compared to JPY 4,972 million a year ago. Profit before tax was JPY 6,175 million compared to JPY 4,311 million a year ago. Profit for the year was JPY 4,413 million compared to JPY 2,642 million a year ago. Profit attributable to owners of parent was JPY 4,296 million or JPY 54.72 per diluted share compared to JPY 2,535 million or JPY 30.91 per diluted share a year ago.
The company provided consolidated earnings guidance for the fiscal year ending December 31, 2018. The company forecast revenue of JPY 162,000 million, operating profit of JPY 10,000 million, Profit before tax of JPY 9,000 million, Profit for the year attributable to owners of the company of JPY 5,900 million or JPY 82.89 per share.
The company provided dividend guidance for the fiscal year ending December 31, 2018. The company expects year-end dividend of JPY 8 per share compared to JPY 8 per share paid a year ago.
NIKKISO CO.,LTD. is a Japan-based company principally engaged in the manufacture and sale of industrial pumps, precision equipment and blood related products, among others. The Company operates in two business segments. Industrial Business segment conducts industrial business including the manufacture, sale and maintenance of industrial special pumps, as well as liquefied gas & industrial gas related equipment and devices. The Segment is also involved in precision equipment business, aerospace business and deep ultraviolet light emitting diode (LED) business. Medical Business segmentâs products are dialysis-related products including hemodialysis and peritoneal dialysis, such as artificial dialysis machines, dialyzers, blood circuits, and powder-type dialysis agents. The Segment also manufactures, sells and maintains products and medicines related to CRRT (acute blood purification therapy), artificial pancreas devices that manage blood glucose, and energy devices for microwave surgery.
Nikkiso Co. Ltd. Announces Consolidated Earnings Results for Nine Months Ended September 30, 2018; Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2018; Provides Dividend Guidance for the Fiscal Year Ending December 31, 2018